Alyeska Investment Group
TOVX icon

Alyeska Investment Group’s Theriva Biologics TOVX Stock Holding History

Alyeska Investment Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-201
Closed -$1.26M – 527
2017
Q3 		$1.64M Sell
201
-260
-56% -$1.5M 0.01% 378
2017
Q2 		$2.28M Sell
461
-14
-3% -$69.7K 0.02% 343
2017
Q1 		$2.62M Sell
475
-49
-9% -$342K 0.02% 375
2016
Q4 		$3.5M Buy
+524
New +$5.38M 0.03% 356
2015
Q4 		– Sell
-31
Closed -$625K – 463
2015
Q3 		$625K Buy
+31
New +$763K 0.01% 415

Other funds holding TOVX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Alyeska Investment Group's TOVX Position: Q4 2017 in Review

Alyeska Investment Group sold out of Theriva Biologics (TOVX) in Q4 2017, closing a stake of 201 shares — an estimated $1.26M sold.

Alyeska Investment Group first reported a position in TOVX in Q3 2015 and held it in 5 quarters. The position peaked at $3.5M in Q4 2016. 48 funds tracked by Wall St. Rank hold TOVX as of Q4 2017.

  • Alyeska Investment Group reported no remaining Theriva Biologics position as of Q4 2017 after selling out during the quarter.
  • Alyeska Investment Group sold 201 Theriva Biologics shares in Q4 2017, an estimated $1.26M.
  • Alyeska Investment Group first reported a position in Theriva Biologics in Q3 2015 and held it in 5 quarters.
  • Alyeska Investment Group's Theriva Biologics position peaked at $3.5M in Q4 2016.
  • 48 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2017.

Based on Alyeska Investment Group's 13F filing for Q4 2017, filed 14 Feb 2018.